Fibriant
Fibriant develops recombinant Fibrinogen and Thrombin using a CHO cell-based manufacturing platform to create customized healthcare solutions for hemostasis and infection control. Their lead product, RecoSeel™, is a fully recombinant Fibrin-based topical hemostat designed to effectively stop surgical bleeding.
- Biotechnology
Funding
Raised to date
$310KRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Founder details are not available yet.
Product
Problem
Surgical bleeding can be difficult to manage, requiring effective and biocompatible hemostatic agents to ensure patient safety and optimal outcomes. Traditional hemostatic products may have limitations in terms of efficacy, risk of disease transmission, or immunogenicity.
Solution
Fibriant develops and manufactures recombinant human Fibrinogen and Thrombin using a CHO cell-based platform to create customized hemostasis and infection control solutions. Their lead product, RecoSeel™, is a fully recombinant Fibrin-based topical hemostat designed to effectively stop surgical bleeding. By utilizing recombinant technology, Fibriant produces specific variants of human Fibrinogen and Thrombin, allowing for tailored solutions with enhanced safety and efficacy profiles. These recombinant proteins leverage the natural properties of Fibrinogen and Fibrin in hemostasis, tissue repair, and host-defense against infections.
Target Audience
The primary customers are surgeons and other healthcare professionals seeking advanced and reliable hemostatic agents for surgical procedures, as well as pharmaceutical companies looking for recombinant Fibrinogen and Thrombin.
Features
- Fully recombinant Fibrin-based topical hemostat
- Utilizes a CHO cell-based manufacturing platform for cost-effective production
- Produces specific variants of human Fibrinogen and active human Thrombin
- Designed to effectively stop surgical bleeding
- Targets infections caused by MRSA bacteria in pipeline products
- Offers opportunities to provide recombinant Fibrinogen and Thrombin to other companies